Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: kathyh who wrote (56922)	9/3/1999 9:52:00 AM
From: ynot	Read Replies (1) \| Respond to of 90042

saving some juice for the close, if we get there :) ynot ;)

To: kathyh who wrote (56922)	9/3/1999 10:02:00 AM
From: CRay33	Read Replies (1) \| Respond to of 90042

CLGY: They have a medication which supposedly will cure (don't laugh) 'roids without an operation. Phase 3 results in September - Insiders have been buying. Janus recently bought in, and Fidelity owns over 5%. I bought the stock at 7, and it inches up a bit each day. It's starting to get attention. From their website: "The Company's lead product Anogesic© is expected to provide significant improvement in the treatment of anal fissures and hemorrhoids, painful conditions often requiring expensive surgical intervention. Anogesic is undergoing two clinical trials in the United States. Patient enrollment for its Phase III clinical trial for the treatment of chronic anal fissures was completed in July 1999. The lead product candidate using the Company's drug delivery technology is a transdermal testosterone gel for the treatment of testosterone deficiency. A Phase II clinical trial using testosterone is nearing completion. Follow-on products will address female hormone replacement therapy and the transdermal delivery of large molecule drugs for a variety of systemic diseases. " All we need now is Bob Dole as a spokesman.